RxDoctor Payments Data

Bassam Al Homsi, MD

Internal Medicine · Deming, NMNPI 1629021233

Payments from drug & device makers

$480in general payments, 2019–2025

Across 27 payments — averaging $17.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$105
  • AstraZeneca$70
  • AbbVie$49
  • Astellas Pharma US Inc$43
  • Xeris Pharmaceuticals, Inc.$39
  • Abbott$34
  • plus $140 from 7 others

What the payments were for

  • Food & beverage$42388%
  • Education$5812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$480 in reported general payments places this provider in the 75th percentile of 578 internal medicine providers in New Mexico.

See all internal medicine providers in New Mexico

Medicare billing

Part B allowed, 2024
$205,763
Medicare patients
481
Services billed
5,838

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RemicadeInfliximab150$1,054,780
KeytrudaPembrolizumab56$655,525
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$200,298
HumiraAdalimumab13$174,944
OzempicSemaglutide127$157,758
EliquisApixaban238$137,135
TrulicityDulaglutide74$112,201
EnbrelEtanercept14$110,741
JanuviaSitagliptin Phosphate141$104,358
NplateRomiplostim14$102,186
XareltoRivaroxaban114$100,247
JardianceEmpagliflozin107$70,278
FarxigaDapagliflozin Propanediol73$67,962
Cyclophosphamide69$60,573
RybelsusSemaglutide37$53,574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Nplate, Prolia$15$242,55545 claims
Novo NordiskOzempic, Rybelsus$105$211,332164 claims
AbbVieHumira, Qulipta$49$207,91426 claims
Lilly USA, LLCTrulicity, Mounjaro$17$146,317102 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$70$98,814134 claims
GSKTrelegy Ellipta$29$18,01933 claims
Astellas Pharma US IncMyrbetriq$43$8,10714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 578 internal medicine providers in New Mexico.

Other internal medicine in Deming

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →